RESUMO
In the setting of percutaneous coronary intervention (PCI), due to a paucity of data, the optimal dose of aspirin isuncertain. We evaluated the safety of different doses of aspirin after PCI.Methods and results In the PCI-CURE study, 2658 patients with acute coronary syndromes undergoing PCI were stratified into three aspirin dose groups 200 mg (high, n » 1064), 101199 mg (moderate, n » 538), and 100 mg (low, n » 1056). For efficacy, the moderate- (7.4%) and high-dose groups (8.6%) had similar rates of cardiovascular death, myocardialinfarction, or stroke compared with the low-dose group (7.1%). For safety, major bleeding was increased with highdose aspirin [3.9, 1.5, and 1.9% in the high-, moderate-, and low-dose groups; hazard ratio (HR) of high vs. low dose 2.05 (95% CI 1.203.50, P » 0.009]. The net adverse clinical events (death, MI, stroke, major bleeding) favoured low-over high-dose aspirin (8.4 vs. 11.0%, HR 1.31, 95% CI 1.001.73 P » 0.056). Conclusion In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higherdoses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance.